Shippeo Introduces Carbon Visibility and Brings Powerful New Features to Ocean and Road Visibility
9.5.2022 13:28:00 EEST | Business Wire | Press release
Shippeo, a leading provider of global and multimodal shipment visibility, today announced new products and major platform enhancements, as part of their feature-packed 2022 Spring platform release. The updates focus on customer satisfaction, new innovations, performance, and meeting evolving market needs. A new CO2 emissions calculator provides critical information on carbon emissions and other greenhouse gasses from supply chain transport and distribution for shippers, logistics service providers and carriers. Container tracking using Shippeo’s Ocean Visibility solution is now faster and easier with a new user experience and powerful monitoring capabilities. In addition, timesaving usability enhancements, data quality improvements and ETA accuracy advancements are introduced for the company’s market-leading Road Visibility product. Finally with the migration to Google Cloud and Snowflake, significant performance and scalability upgrades are added to the Shippeo platform.
“Our latest Spring platform release is packed full of new features and capabilities for customers,” explains Anand Medepalli, Chief Product Officer at Shippeo, “including a completely new Carbon Visibility offering for accurately calculating CO2 and other greenhouse gas emissions at the shipment level, as well as major enhancements to our Ocean and Road visibility solutions. We are evolving our platform to not only meet the needs of our customers today, but also to solve tomorrow’s supply chain problems. This is the first release in a new twice-yearly Spring and Autumn Shippeo platform release cycle, representing a shift to more regular and regimented platform updates. This reliability and momentum will help us to keep ahead and continue to offer the most innovative real-time visibility platform experience for users, more powerful capabilities to increase productivity, and higher data quality to improve ROI for our customers.”
Accurate, consolidated CO2 emissions monitoring for shippers and carriers
Carbon Visibility
offers shippers and logistics service providers a consolidated view of CO2 emissions for upstream and downstream transport and distribution activities in one place, bringing a number of new capabilities to help companies monitor progress towards sustainability objectives.
Carriers also benefit from the new Carbon Visibility offering, allowing them to avoid the time consuming manual work that they are faced with today to calculate emissions on behalf of their clients. Carriers can now use Shippeo to instantly generate CO2 emission reports, which should allow them to more easily allocate CO2 emissions from a single vehicle to multiple customers in LTL/groupage scenarios based on their business rules.
The Shippeo Carbon calculator follows the GLEC framework and is compliant with EN 16258 and GHG protocol.
Advanced container tracking over ocean
Major enhancements to
Ocean Visibility
will help supply chain and transport managers track and manage container shipments more productively, with new features and a revamped user experience, including:
- More detailed container event information with new AIS-based milestones and precise geofencing
- A revamped order detail page displaying all relevant container tracking information
- Ability to identify deviations from status information provided by ocean carriers
- An updated global map providing a holistic view of ocean shipments, by vessel or individual container
- New filters making searching for containers easier
- Higher overall data quality with inputs from new data sources
Road tracking enhancements
Timesaving usability enhancements, data quality improvements and ETA accuracy advancements are introduced for
Road Visibility
, offering customers an even more powerful over-the-road shipment tracking solution.
- ETA accuracy improves 32% thanks to AI/ML algorithm advancements, upgraded Dataiku ML Ops platform infrastructure and data science methodology advancements
- Shuttle flow tracking enables better differentiation between shipments within multiple back-and-forth tours for more accurate departure and arrival times
- Quality Newsletters notify users of data tracking rates and provides steps for improving tracking quality
- Improved visibility and readability of information, with new tagged events and links between map and timeline views
Infrastructure improvements to boost data quality and user experience
Shippeo’s platform has been migrated to Google Cloud Platform in its entirety, representing a major improvement in infrastructure. The shift ensures significant scalability, performance and localization capabilities along with enhanced security for customers.
Alongside the platform feature additions and enhancements, Shippeo has also continued to double-down on higher data quality, an area in which the company consistently leads the market. Continued investment of significant capital into R&D aims to advance the platform’s AI/ML capabilities even further.
To that point, the data warehouse powering Shippeo Insights is now migrated to Snowflake, a state-of-the-art high-performance analytics database that has managed to reduce Shippeo dashboard loading times by 50% on average and up to 90% for large customers.
About Shippeo
Shippeo, a global leader and European specialist in real-time transportation visibility, helps major shippers and logistics service providers leverage transportation to deliver exceptional customer service and achieve operational excellence. Their Multimodal Visibility Network connects FTL, LTL, parcel, and container transport and integrates 875+ TMS, telematics and ELD systems using a unique API. The Shippeo platform provides instant access to real-time delivery tracking, automates customer processes and offers unmatched ETA accuracy thanks to a proprietary and industry-leading algorithm developed in-house. Hundreds of customers, including global brands like Coca-Cola HBC, Carrefour, Renault Group, Schneider Electric, Total, Faurecia, Saint-Gobain and Eckes Granini, trust Shippeo to track more than 28 million shipments per year across 75 countries. Learn more at www.shippeo.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220505005569/en/
Contact information
Europe: Andrea Krug, Krug Communications Ltd, Tel. +44 (0)7740 245 867, email: andrea@krugcomms.com
North America: Carol Kraeutler Lerner, CKL Communications, Tel. +1 (201) 602-7572, email: ckl.communications@gmail.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
